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Abstract
Background: Prior to the start of cross-sex hormone therapy (CSH), androgenic progestins are often used to induce
amenorrhea in female to male (FtM) pubertal adolescents with gender dysphoria (GD). The aim of this single-center
study is to report changes in anthropometry, side effects, safety parameters, and hormone levels in a relatively large
cohort of FtM adolescents with a diagnosis of GD at Tanner stage B4 or further, who were treated with lynestrenol
(Orgametril®) monotherapy and in combination with testosterone esters (Sustanon®).
Methods: A retrospective analysis of clinical and biochemical data obtained during at least 6 months of hormonal
treatment in FtM adolescents followed at our adolescent gender clinic since 2010 (n = 45) was conducted.
McNemar’s test to analyze reported side effects over time was performed. A paired Student’s t test or a Wilcoxon
signed-ranks test was performed, as appropriate, on anthropometric and biochemical data. For biochemical
analyses, all statistical tests were done in comparison with baseline parameters. Patients who were using oral
contraceptives (OC) at intake were excluded if a Mann-Whitney U test indicated influence of OC.
Results: Metrorrhagia and acne were most pronounced during the first months of monotherapy and combination
therapy respectively and decreased thereafter. Headaches, hot flushes, and fatigue were the most reported side
effects. Over the course of treatment, an increase in musculature, hemoglobin, hematocrit, creatinine, and liver
enzymes was seen, progressively sliding into male reference ranges. Lipid metabolism shifted to an unfavorable
high-density lipoprotein (HDL)/low-density lipoprotein (LDL) ratio; glucose metabolism was not affected. Sex
hormone-binding globulin (SHBG), total testosterone, and estradiol levels decreased, and free testosterone slightly
increased during monotherapy; total and free testosterone increased significantly during combination therapy.
Gonadotropins were only fully suppressed during combination therapy. Anti-Müllerian hormone (AMH) remained
stable throughout the treatment. Changes occurred in the first 6 months of treatment and remained mostly stable
thereafter.
Conclusions: Treatment of FtM gender dysphoric adolescents with lynestrenol monotherapy and in combination
with testosterone esters is effective, safe, and inexpensive; however, suppression of gonadotropins is incomplete.
Regular blood controls allow screening for unphysiological changes in safety parameters or hormonal levels and for
medication abuse.
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Background
Gender dysphoria (GD), formerly referred to as gender
identity disorder [1–3], is defined as the discrepancy be-
tween the expressed or experienced gender and one’s
natal gender, which causes distress or impairment in im-
portant areas of functioning. It is increasingly recognized
that many transsexual adults have experienced GD
already from childhood onwards [4]. The Endocrine So-
ciety clinical practice guideline, published in 2009, rec-
ommends medical treatment and psychological guidance
of children and adolescents with GD [5].
Because GD will persist after puberty in only a minor-
ity of the children presenting with GD, medical treat-
ment, i.e., puberty suppression is best started after the
first physical signs of puberty [4, 6]. At the onset of pu-
berty, the reaction of the adolescent to the first bodily
changes, under the form of increasing aversion of their
biological sex which will enhance GD, often provides
additional diagnostic evidence [7]. If GD persists, the
child will be eligible for medical treatment aimed at sup-
pressing puberty and/or attenuating its physical symp-
toms [5, 8], a decision which is to be made by an
experienced multidisciplinary team. However, delaying
puberty is controversial. The general consensus now-
adays tends to be that the advantages of reducing psy-
chological burden, giving more time to explore gender
identity and decreasing the need for (and extent of ) later
sex reassignment surgery [4] outweigh the disadvantages.
Arguments against puberty suppression include that the
gender identity of adolescents is still developing during
puberty and suppression of endogenous sex hormones
may interfere with normal growth, bone maturation, and
brain development. However, with the initiation of
cross-sex hormones, these effects are believed to be
(mostly) reversible [9].
To suppress endogenous gonadal hormones in female
to male (FtM) adolescents and enlighten the psycho-
logical burden of menstruation, two treatment options
are available: Gonadotropin releasing-hormone analogs
(GnRHa) and progestins. Although prospective random-
ized clinical trials focussing on physical changes, side ef-
fects, and psychological outcome have never been
performed, GnRHa are often preferred because they
more effectively reduce endogenous ovarian hormone
production [5]. However, in many countries, expensive
GnRHa are not reimbursed to treat GD, and in these
cases, androgenic progestins are a valuable alternative to
induce amenorrhea, especially in adolescents who
already have advanced development of secondary sex
characteristics at the start of treatment or in adults [10].
Lynestrenol (L) (Orgametril®) 5 mg is approximately 13
times cheaper than GnRHa (€85 versus €1100 per year
in Belgium), and as it is taken orally, it does not require
intramuscular injections. Both medications are not
reimbursed to treat adolescents with GD in Belgium and
are at the expense of patients. For these reasons, L is
mostly used in our center to suppress menstruation in
FtM adolescents with an established diagnosis of persist-
ing GD at Tanner stage B4 or further who are not eli-
gible yet for cross-sex hormones (CSH) therapy in view
of their young age [10].
L is a prodrug that is converted to norethisterone [11].
It is an androgenic, first generation progestin of the 19-
nortestosterone steroids family that is commonly used as
hormonal replacement therapy in postmenopausal
women or to treat endometriosis [12]. Older studies
have revealed that 19-nortestosterone derivates moder-
ately decrease serum triglyceride levels and deteriorate
glucose tolerance in women with already impaired insu-
lin secretion. In healthy young women however they will
not alter glucose metabolism [13, 14]. The induction or
increase of acne and hirsutism by androgenic progestins
results from reduction of estradiol and sex hormone-
binding globulin (SHBG) levels, leading to higher abso-
lute and relative concentrations of endogenous andro-
gens and unbound androgenic progestins [15]. No
studies exist on the long-term use of lynestrenol or other
progestins for the treatment of FtM gender dysphoric
adolescents.
In our center, CSH under the form of testosterone es-
ters (TE), Sustanon® is added to the treatment from
16 years onwards if GD persists and if the adolescent in-
creasingly lives in the male gender role. This age criter-
ion, although recommended by the Endocrine Society
guidelines in 2009 [5], is actually under debate and will
likely be adjusted in a revised version [5], which is cur-
rently in preparation. Most importantly, the decision to
start CSH is made by the multidisciplinary team, in ac-
cordance with the adolescent and her/his parents. In-
creasing doses of intramuscular TE are administered
according to a strict protocol, starting with an initial
dose of 50 mg every 2 weeks. Every 6 months the dose is
increased with 25 mg until an average adult dose of
125 mg per 2 weeks is reached. Between the ages of 17
and 19, an initial dose of 100 mg TE per 2 weeks is
given, which is increased to 125 mg after 6 months.
After having reached an adult replacement dose, long-
acting testosterone undecanoate injections (Nebido®) are
often considered more convenient.
The effects of TE administration have been well stud-
ied in adults. It will increase facial and body hair, libido,
muscle mass, and the oiliness of the skin. It will also re-
sult in clitoromegaly, a deeper voice, cessation of men-
ses, redistribution of fat mass, and in some cases male
pattern balding [5, 16-19]. Although testosterone admin-
istration may cause hypercholesterolemia, hypertension,
and reduced high density lipoprotein (HDL) levels, there
is no evidence that this increases cardiovascular
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pathology in FtM transsexuals [20]. During treatment,
bone mass density will be maintained because of aroma-
tisation of testosterone to estradiol [21, 22]. Although
rare, induction of hormone-related cancers such as car-
cinomas of the female genital tract and breasts due to
testosterone administration has been reported [23, 24].
The use of TE in adolescents with GD specifically has
not been studied. It is hypothesized that the same bodily
changes, side effects, and hormonal shifts occur as in
adults. It was shown recently that TE from 16 years on-
wards can only partially reverse the decline in bone mass
density observed during puberty suppression with
GnRHa [25,26].
The aim of this single-center study is to retrospectively
analyze the impact of consecutive treatment with L
monotherapy and in combination with TE on physical
characteristics, safety, metabolic parameters, and hor-
mone levels in a relatively large cohort of FtM gender
dysphoric adolescents and to report side effects that oc-
curred during this treatment.
Methods
Patients
Data on 45 gender dysphoric FtM adolescents who had
received hormonal treatment over a period of at least
6 months from 2010 until September 2015 were avail-
able; two adolescents were excluded: one had committed
suicide during the follow-up period, and the family was
not contacted to obtain informed consent, and one did
not consent in use of his data for the study. In five of
the remaining 43 cases, insufficient laboratory data were
available; therefore, only anthropometric data were in-
cluded. In some of the remaining 38, due to the retro-
spective nature of the study and occasional sample loss,
not all parameters were available at each time point.
Treatment consisted of L monotherapy for at least
6 months in all included participants followed by com-
bination therapy of L and TE (L+T) in a subset of them
(n = 25) for at least 6 months. The others were too
young to be eligible for CSH therapy at the time of data
analysis. Criteria to start CSH therapy were based on the
Endocrine Society guidelines [5]. Adolescents who had
low vitamin D levels were advised to take vitamin D
supplementation and a calcium enriched diet during
treatment.
Methods
Intake visits were aimed at excluding a disorder of sex
development underlying GD and at determining the pu-
bertal (Tanner) stage. L was started in FtM adolescents
with Tanner stage B4 and further, who met the criteria
as outlined in the Endocrine Society guidelines [5]. TE
were added to the treatment according to the protocol
represented in Table 1, in FtM adolescents of at least
16 years old who met the criteria as outlined in the
Endocrine Society guidelines [5]. Follow-up visits were
scheduled every 6 months. At each visit, the following
parameters were recorded:
Medical history including family and personal medical
history, life style factors (such as smoking habits and
alcohol consumption), psychiatric comorbidity, and
effects and side effects of the medication. Patients were
clearly instructed that in case of metrorrhagia, they
should double the L dose for 10 days
Physical examination: anthropometry, blood pressure,
Tanner stage, acne, and hirsutism
Biochemical analyses: every 6 months: complete blood
count, electrolytes, liver and renal function, thyroid-
stimulating hormone (TSH), free thyroxin (fT4),
luteinizing hormone (LH), follicular stimulating hor-
mone (FSH), estradiol (E2), total and free testosterone
(T and fT), and sex hormone-binding globuline
(SHBG). Every year: fasting glucose, insulin, lipid me-
tabolism, and anti-Müllerian hormone (AMH). During
medical treatment, patients are seen every 3 months by
the team child psychologist. In the absence of psychi-
atric comorbidity, they are evaluated twice by the team
child psychiatrist during this phase; once before initi-
ation of L and once more at start of L+T. Fertility is-
sues are discussed thoroughly throughout each
treatment phase, and adolescents are given the chance
to undergo ovum pick-up following an ovarian stimula-
tion program before initiation of T. However, most—if
not all—adolescents prefer to start TE without any
delay. When considering sex reassignment surgery,
Table 1 Schedule of increments of testosterone administration and vitamin D supplementation
Schedule 16 years Schedule 17–19 years
Time Substance Dose DI Time Substance Dose DI
Start Sustanon 50 mg Every 2 w Start Sustanon 100 mg Every 2 w
6 m Sustanon 75 mg Every 2 w 6 m Sustanon 125 mg Every 2 w
12 m Sustanon 100 mg Every 2 w 12 m Sustanon 125 mg Every 2 w
18 m Sustanon 125 mg Every 2 w 18 m Sustanon 125 mg Every 2 w
+Vit D 25,000 U every 4 w oral + calcium intake of 1200–1500 mg/day
m months, w weeks, DI dose interval
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adolescents are again given the above option or, alter-
natively, part of their ovaries can be cryopreserved at
the time of gonadectomy. In our experience, most pa-
tients prefer the second option.
Statistical analysis was performed using IBM SPSS
software package (version 22). A P value of less or equal
to 0.05 was considered significant. McNemar’s test for
comparison of paired data was performed to analyze re-
ported side effects over time. After testing for normality,
anthropometric and biochemical data were analyzed
using a paired Student’s t test or a Wilcoxon signed-
ranks test as appropriate. For biochemical analyses, all
statistical tests were done in comparison with baseline
parameters (at start of L or L+T). Eight patients were
using oral contraceptives (OC) at intake. Data obtained
in these patients at intake were excluded from analyses
if a Mann-Whitney U test indicated influence of OC.
Methods of measurements of the biochemical parame-
ters are represented in Table 4. The detection limit for
LH, E2, and T (RIA) was 0.1 U/L, 25 ng/L, and 10 ng/dL,
respectively. The maximal detection limit for SHBG was
200 nmol/L. In case of values below or above these limits,
the limit itself was inputted for statistical analyses.
Approval of the ethics committee of Ghent University
hospital was obtained (B670201525328). All patients
were contacted by mail and could object against use of
their data for the study.
Results
Patient and treatment characteristics
Data on educational level, comorbidities, and lifestyle
characteristics are represented in Table 2.
Mean age at start of L and L+T was 15 years
10 months, and 17 years 5 months, respectively. Mean
treatment duration for L was 12.6 months and for L+T
11.4 months. No patients stopped treatment because
they no longer wished to pursue gender reassignment.
Side effects
Reported side effect is shown in Table 2. Headaches and
hot flushes were reported during L monotherapy,
whereas fatigue was a complaint during both L and L +
T. One of the four patients with hot flushes stopped
treatment because of this side effect. During L, there
was a non-significant increase in acne (P = 0.125); how-
ever, the prevalence of acne significantly increased in the
first 6 months of L+T (P = 0.021), requiring treatment
with oral retinoic acid in three out of 13 individuals. Me-
trorrhagia was mainly reported in the first 6 months of
L but significantly dropped in the next 6 months (P =
0.004). During L+T, the prevalence of metrorrhagia in-
creased slightly over the course of treatment.
Anthropometry
Mean height at start of L was 164.6 cm, and at start of L
+T, it was 167.6 cm. Weight and body mass index (BMI)
significantly increased in the first 6 months (P = 0.004
and P = 0.031, respectively), but had turned back to base-
line after 12 months of L (P = 0.538 and P = 0.918, respect-
ively). L+T was associated with a significant and
continuous weight gain after 6 months (P = 0.023 and
P = 0.003) and 12 months (P = 0.002 and P = 0.015, re-
spectively). This increase in weight and BMI was sig-
nificantly different from weight changes in age-
matched same biological sex peers, based on standard
deviation (SD) scores [27]. Evolution of weight and
BMI are represented in Table 3.
Biochemical analyses
Safety and metabolic parameters
Mean hemoglobin (Hb) and hematocrit (Hct) levels in-
creased significantly in the first 6 months of L and of L
+T but remained stable in the next 6 months. None of
the individual Hb values rose above the upper adult male
reference (Fig. 1a, b).
Table 2 Summary of patient characteristics and side effects
Comorbidity Education Side effects
Psychiatric: 11/43 (25.6 %)
Social problems: 7/43 (16.3 %)
DSD: 0/43 (0 %)
ASO: 9/42 (21.4 %)
TSO: 16/42 (38.1 %)
BSO: 11/42 (26.2 %)
BUSO: 4/42 (9.5 %)
KSO: 2/42 (4.8 %)
Time Metrorrhagia Acne
L0L6mL12mL + T0L












Smoking Alcohol Time Headache Hot flushes fatigue
No: 34/43 (79.1 %)
Moderate: 9/43 (20.9 %)
High: 0/43 (0 %)
No: 24/43 (55.8 %)
Yes: 19/43 (44.2 %)






Smoking: Moderate: 1 to 20 cigarettes a day, high: >20 cigarettes a day
ASO theoretical education, TSO technical education, BSO vocational training, BUSO school for children with learning difficulties, KSO art school, L lynestrenol
monotherapy, L+T lynestrenol and testosterone esters combination therapy
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Only alanine amino transferase (ALT) but not aspar-
tate amino transferase (AST) showed a statistically sig-
nificant, although not clinically relevant rise after
12 months of L. In one patient, ALT levels transiently
increased above the upper male reference to 57 U/L
after 12 months of L but normalized after the start of L
+T. Both ALT and AST further increased under L+T
treatment but remained well within the male reference
range. None of the patients reached the threshold of
three times the upper reference limit which we consid-
ered the cutoff to stop treatment (Fig. 1c, d). Creatinine
significantly increased during the first 6 months of L
and during the first 6 months of L+T but remained
stable in the following 6 months (Fig. 1g).
Total cholesterol and triglyceride levels did not change
during treatment; however, mean HDL decreased signifi-
cantly and mean low-density lipoprotein (LDL) levels in-
creased significantly in the first 6 months of L. During L
+T, mean LDL levels did not change significantly (Fig. 1e,
f ). No significant changes in hemoglobin A1c (HbA1c),
glucose levels, insulin levels, or homeostasis model as-
sessment (HOMA) index were noticed during either L
or L+T treatment.
Hormone levels
Although no significant changes in mean TSH levels
were observed, fT4 levels increased significantly both in
the first and second half year of L. In the first 6 months
of L+T, there was a decrease in TSH accompanied with
a significant and consecutive decrease in fT4 in the first
and next 6 months of treatment. However, in all pa-
tients, serum levels for both TSH and fT4 remained well
within the reference range (Table 4). The eight patients
who were using OC before L was started were excluded
for baseline analysis of LH, FSH, E2, A, and SHBG.
Mean AMH, T, and fT levels were not different in OC
users as compared to non-OC users and were included
in baseline analyses.
Mean SHBG, LH, but not FSH levels decreased sharply
during the first 6 months of L and remained unchanged
in the next 6 months (Fig. 1h). Only after L+T, LH and
FSH were both fully suppressed (Fig. 1i). L caused a sig-
nificant decrease in mean E2 levels at 6 months with no
significant changes anymore thereafter (Fig. 1j). Mean
AMH levels did not change during the course of
treatment.
The significant decrease in T levels in the first
6 months of L was accompanied by a non-significant in-
crease in fT . Both T and fT did not change in the next
6 months. As expected, mean T increased significantly
in the first months of L+T, already at the lowest dose
(50 mg/2 weeks) and further increased in the next
months to reach T values well within the male reference
range. This was accompanied by a similar increase in fT
levels. Some patients exceeded the male upper reference
of 25 ng/dL, due to blood sampling close to the last TE
injection (Table 4 and Fig. 1k,l).
Discussion
Androgenic progestins are a cheap alternative for
GnRHa to suppress menses in gender dysphoric FtM ad-
olescents. They are therefore preferred in situations
where GnRHa are not reimbursed, especially in older ad-
olescents who already have advanced pubertal develop-
ment at the time of diagnosis, either as monotherapy
while the adolescent is awaiting eligibility (depending on
the local team’s criteria) to start cross-sex hormone
treatment or in combination with the latter to reinforce
its effects. Since no data are available on the safety pro-
file and effects of progestins in general and L in particu-
lar for this indication, we analyzed these parameters
retrospectively in a relatively large cohort of FtM adoles-
cents treated in our center between 2010 and 2015. Our
study population did not differ from the adolescent Bel-
gian population in terms of educational level, smoking
habits, and alcohol consumption [28–30].
The most frequently reported side effects were metror-
rhagia (almost 50 % after 6 months of L) and acne (al-
most 60 % after 6 months of L + T but also prevalent
during L). In many but not all cases, metrorrhagia was
Table 3 Summary of analysis of antropometric data
L0 L6m P (L0-6 m) L12m P (L0–12 m) L+T0 L+T6m P (L+T0–6 m) L+T12m P (L+T0–12 m)
Weight 61.48 63.98 0.004 61.03 0.007a 58.65 61.18 0.023 65.10 0.001
SD 0.16 0.36 0.120 0.01 0.911 −0.38 −0.13 0.016 0.01 0.001
BMI 22.58 23.00 0.031 22.39 0.193b 20.69 22.38 0.003 23.26 0.004
SD 0.21 0.43 0.098 0.18 0.719 −0.34 0.20 0.011 0.24 0.004
SD standard deviation in comparison with Flemish peers [27], L0 mean values before initiation of L, L6m mean values after 6 months of L; P(L0–6 m) P values of
comparison of baseline parameters with values after 6 months of L, L12m mean values after 12 months of L, P(L0–12 m) P values of comparison of baseline
parameters with values after 12 months of L, L+T0 mean values before initiation of L+T, L+T6m mean values after 6 months of L+T, P(L+T0–6 m) P values of
comparison of baseline parameters with values after 6 months of L+T, L+T12m mean values after 12 months of L+T, P(L+T0–12 m) P values of comparison of
baseline parameters with values after 12 months of L+T, L lynestrenol monotherapy, L+T lynestrenol and testosterone esters combination therapy
aAlthough mean weight of all patients seems to decrease, a significant increase in weight was noted when comparing weight at baseline with weight after
12 months of L. This discrepancy is caused by exclusion of patients, who had not yet reached 12 months of L at time of analysis
bBMI non-significantly increased after 12 months of L, although mean BMI seems to decrease. This is due by the same phenomenon as described in a
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limited and could be controlled by doubling the L dose
during 10 days; metrorrhagia tends to be less prevalent
with longer treatment duration. An increase in acne in
women during androgenic progestins or androgen ad-
ministration is a well-known phenomenon [10, 17, 18,
31, 32]. However, adolescents are particularly vulnerable
for this side effect. In 3/13 (23.1 %) of adolescents with
acne during L+T, vitamin A analogs were required.
Combining L+T with vitamin A analogs did not lead to
exacerbation of liver enzymes or important changes in
other safety parameters.
Consecutive L and L+T treatment does not seem to
interfere with residual growth. In contrast, weight and
BMI significantly increased during L+T as compared to
age-matched same biological sex peers, which is most
likely due to changes in lean body mass, as is seen in
athletes who use androgenic anabolic steroids [32]. Lon-
gitudinal standardized assessment of body composition
is necessary to confirm this hypothesis.
Analysis of safety parameters was mostly reassuring,
and no patients had to stop treatment because of an ad-
verse safety profile: Throughout the treatment,
hemoglobin, hematocrit, and creatinine shifted into, but
did not exceed, the male reference range. Indeed, andro-
gens are known to stimulate erythropoiesis, renal
erythropoietin production [31, 33], and muscle mass
[34]. Similarly, liver enzymes increased during L+T but
remained well within the male reference range in all pa-
tients. Since androgens have been shown to (transiently)
elevate liver enzymes, rarely causing severe liver disease
[32, 35–39], we advise close monitoring during treat-
ment. Consistent with other studies [13, 14, 31], no
changes in HbA1c, insulin, glucose, or HOMA index
were found during the entire course of treatment. Im-
portantly, our treatment regimen resulted in a more un-
favorable lipid profile. Similar findings have been
reported, mostly in adults [40, 41]. However, there are
currently no data available on the metabolic profile and
cardiovascular risk in older adult transmen who changed
Fig. 1 Box-and-whisker plots of biochemical parameters. L0 baseline
values, L6m after 6 months of L, L12m after 12 m of L, L+T0 before
start of L+T, L+T6m after 6 months of L+T, L+T12m after 12 months
of L+T. a Hemoglobin (g/dL, multiply by 10 for SI units: g/L); b
hematocrit (%, multiply by 0,01 for SI units: proportion of 1.0); c AST
(U/L, multiply by 0.0167 for SI units: μkat/L); d ALT (U/L, multiply by
0.0167 for SI units: μkat/L); e HDL (mg/dL, multiply by 0.0259 for SI
units: mmol/L); f LDL (mg/dL, multiply by 0.0259 for SI units: mmol/
L); g creatinine (mg/dL, multiply by 88.4 for SI units: μmol/L); h sex
hormone-binding globulin (nmol/L); i luteinizing hormone (U/L); j
estradiol (ng/L, multiply by 3.671 for SI units: pmol/L); k testosterone
(ng/dL, multiply by 0.0347 for SI units: nmol/L); l free testosterone
(ng/dL, multiply by 34.7 for SI units: pmol/L). L lynestrenol mono-
therapy; L+T lynestrenol and testosterone esters combination ther-
apy, AST/ALT aspartate/alanine amino transferase, HDL/LDL high/low
density lipoprotein
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Table 4 Summary of the analysis of biochemical data
TestMethod of measurement L0 L6m P (L0–6 m) L12m P (L0–12 m) L+T0 L+T6m P (L+T0–6 m) L+T12m P (L+T0–12 m)
HemoglobinSpectrophotometry
(Sysmex XE-5000)
133.7 142.4 <0.001 141.4 0.001 143.3 148.5 <0.001 149.7 <0.001
Reference (g/L): M < 18 y: 130–160, M > 18 y: 129–173, F < 18 y: 120–160, F > 18 y: 118–148
HematocritDC impendance
(Sysmex XE-5000)
0.400 0.417 <0.001 0.418 0.003 0.419 0.435 0.002 0.438 <0.001
Reference (proportion of 1.0): M < 18 y: 0.37–0.49, M > 18 y: 0.39–0.497, F < 18 y: 0.36–0.46, F > 18 y: 0.358–0.437
CreatinineRate-blanked Jaffé
kinetic assay (Roche Diagnostics
c701 (a + b))
65.416 71.604 <0.001 70.72 <0.001 69.836 73.372 0.052 72.488 0.045
Reference (μmol/L): M/F: 11–13 y: 46.852–69.836, M/F: 13–15 y: 50.388–76.908, M > 15 y: 63.648–103.428, F > 15 y: 48.62–84.864
Aspartate amino transferase
UV-kinetic (IFCC) method without
pyridoxal phosphate (Roche
Diagnostics Cobas c701)
0.30 0.31 0.903 0.33 0.091 0.31 0.35 0.031 0.35 0.003
Reference (μkat/L): M 0–0.62, F 0–0.52
Alanine amino transferaseUV-kinetic
(IFCC) method without pyridoxal
phosphate (Roche Diagnostics
Cobas c701)
0.22 0.27 0.121 0.31 0.012 0.28 0.31 0.079 0.34 0.045
Reference (μkat/L): M 0.12–0.67, F 0.12–0.52
TriglyceridesEnzymatic colorimetric
method (GPO-PAP and CHOD-PAP,
Roche Diagnostics c701 (a + b))
0.838 0.870 0.31 0.661 0.128 0.651 0.934 0.18 1.394 0.18
Reference (mmol/L): M 10–15 y: 0.362–1.413, M 15–20 y: 0.418–1.672, F 10–15 y: 0.418–1.48; F 15–20 y: 0.441–1.492
Total cholesterolEnzymatic colorimetric
method (GPO-PAP and CHOD-PAP,
Roche Diagnostics c701 (a + b))
4.153 4.348 0.182 4.237 0.218 4.212 4.099 0.504 4.450 0.11
Reference (mmol/L): M 10–15 y: 3.082–5.232, M 15–20 y: 2.927–5.102, F 10–15 y: 3.212–5.206, F 15–20 y: 3.108–5.258
High density lipoproteinEnzymatic
colorimetric method (Roche
Diagnostics c701 (a + b))
1.481 1.096 <0.001 1.017 0.002 1.098 1.194 0.419 1.085 0.77
Reference (mmol/L): M: 0.829–1.865, F: 1.010–2.486
Low density lipoproteinCalculated 2.379 3.057 0.001 2.750 0.043 2.794 2.267 NA 3.163 0.09
Reference (mmol/L): M < 20 y: 1.606–3.626, F < 20 y: 1.735–3.626
Hemoglobin A1cIon-exchange
chromatography (Tosoh HLV-723G8)
0.052 0.051 0.228 0.052 0.34 0.051 0.052 0.102 0.051 0.317
Reference (proportion of 1.0): M/F 0.04–0.055
Homeostasis Model Assessment
insulin resistanceCalculated
2.99 3.11 0.122 2.43 0.396 2.45 4.84 NA 7.44 0.185
Reference: M during puberty <5.22, F during puberty <3.82 or M/F <4.39 [55, 56]
Thyroid-stimulating hormone
Electro-chemoluminescence assay
(Roche Diagnostics E170 Modular)
2.07 2.06 0.757 2.1 0.257 2.25 1.83 0.013 2.22 0.271
Reference (mIU/L): M/F 11–20 y: 0.51–4.3
Free thyroxinElectro-chemoluminescence
assay (Roche Diagnostics E170 Modular)
15.959 17.375 0.006 19.820 <0.001 18.275 16.216 0.001 14.543 0.003
Reference (pmol/L): M/F 12-20 y: 12.613-20.978
Lutheinizing hormone
Electro-chemoluminescence
assay (Roche Diagnostics E170 Modular)
7.56 4.63 0.065 2.58 0.042 3.41 1.93 0.004 1.68 0.028
Reference (IU/L): M 1–9 U/L, F 1–96 U/L (cycle dependant)













Table 4 Summary of the analysis of biochemical data (Continued)
Follicular-stimulating hormone
Electro-chemoluminescence assay
(Roche Diagnostics E170 Modular)
Reference (IU/L): M 1–12 U/L, F 2–22 U/L (cycle dependant)
Sex hormone-binding globulin
Electro-chemoluminescence assay
(Roche Diagnostics E170 Modular)
77.14 20.88 <0.001 19.15 0.001 30.34 25.27 0.279 23.51 0.279
Reference (nmol/L): M < 70 y: 11.6–71.2, F < 50 y: 10.5–163.7
EstradiolElectro-chemoluminescence
assay (Roche Diagnostics E170 Modular)
277.564 119.895 0.002 120.225 0.122 117.802 175.841 0.107 156.348 0.701
Reference (pmol/L): M 99.484–191.626, F 98.016–1152.694 (cycle dependant)
Testosteroneliquid chromatography
tandem mass spectrometry (LC/MSMS)
0.950 0.667 0.002 0.663 0.687 0.844 15.559 <0.001 19.532 0.001
Reference (nmol/L): M 11.139–34.874, F < 50 y 0.291–1.669
Free testosteroneCalculated 15.962 24.290 0.209 21.861 0.138 25.678 295.297 0.005 472.614 0.008
Reference (pmol/L): M 208.2–867.5, F 0.694–22.208
Anti-Müllerian hormoneEnzyme-linked
immunosorbent assay (Beckman
Coulter Company) until 2/2015,
thereafter electro-chemoluminescence
assay (Roche Diagnostics E170 Modular)
33.214 25.714 0.066 24.000 0.423 24.357 28.429 0.18 27.072 0.575
Reference (pmol/L): M 6–20 y 11.429–1028.578 (Tanner), F 8–20 y: 4.7143–60.143
L0 mean values before initiation of L, L6m mean values after 6 months of L, P(L0–6 m) P values of comparison of baseline parameters with values after 6 months of L, L12m mean values after 12 months of L, P(L0–
12 m) P values of comparison of baseline parameters with values after 12 months of L, L+T0 mean values before initiation of L+T, L+T6m mean values after 6 months of L+T, P(L+T0–6 m) P values of comparison of
baseline parameters with values after 6 months of L+T, L+T12m mean values after 12 months of L+T, P(L+T0–12 m) P values of comparison of baseline parameters with values after 12 months of L+T, NA not available
due to insufficient data, L lynestrenol monotherapy, L+T lynestrenol and testosterone esters combination therapy, M male reference, F female reference, Y years old, cycle dependant different reference ranges
according to different stages of menstrual cycle (maximum upper and lower limit of all cycle stages are represented), Tanner different reference ranges according to different Tanner stages (maximum upper and













their gender during adolescence [25]; this finding merits
attention, and further research in transsexual adults fo-
cusing on early determinants of cardiovascular disease
such as adiponectin or carotid artery intima media thick-
ness is warranted.
The expected hormonal changes of L were obvious
after 6 months of monotherapy: T had decreased by al-
most 30 % whereas E2 had decreased by almost 60 %.
The overall decrease in the estrogenic to androgenic ra-
tio is a common property of all androgenic progestins
[15, 40, 42]. Similarly, cross-sex hormone therapy re-
sulted in mean T levels within the male reference range
already after 6 months and with the lowest doses of
50 mg T per 2 weeks only. The non-significant rise in
E2 levels during L+T likely represents the effect of
aromatisation of the injected testosterone esters.
LH, but not FSH, was only partially suppressed by L
monotherapy. Complete suppression of both gonadotro-
pins was only achieved during L+T.
(Androgenic) progestins have been shown to reduce
TBG levels, resulting in an increase in fT4 [43], which
was also observed in our study. During L+T, TSH transi-
ently and fT4 persistently decreased. The impact of sex
steroids on thyroid function is poorly understood and
various studies have yielded conflicting data [44, 45].
Overall, changes in TSH and fT4 were small in our
study and did not result in clinical or biochemical hypo-
or hyperthyroidism. Therefore, we did not consider them
as clinically relevant.
Whether or not long-term androgen exposure in natal
women alters the ovarian follicle reserve, limiting the
possibilities for successful ovarian cryopreservation and
subsequent in vitro follicle maturation, is currently de-
bated. In primates, androgen administration has been
shown to stimulate early follicular growth, after which
further development is stopped due to suppression of
gonadotropin secretion, resulting in an ovarian morph-
ology similar to polycystic ovary (PCO) syndrome and
increased AMH levels [46–49]. Similar PCO-like
changes have been observed in ovaries of transmen after
salpingo-oophorectomy; however, this was not con-
firmed in a more recent study [50–53]. In contrast with
the study of Caanen et al. [54] where AMH levels were
strongly reduced using a combination of T, an aromatase
inhibitor, and a GnRHa to treat GD in adult natal
women, AMH levels did not significantly change in our
patients. Further clinical and pathological studies are
needed to examine the impact of androgen treatment on
AMH levels and ovarian morphology and follicle reserve
in natal women with GD.
Our study has the typical limitations of a retrospective
analysis, such as a number of missing data and the im-
possibility to draw causal relationships. Reported side ef-
fects were limited to those recorded in the patient’s files
and can therefore be an underestimation. Strengths of
our study are the relatively large and homogenous pa-
tient population and the fact that this is a single center
study where all patients were treated by only two differ-
ent observers and received the same treatment regimen
and follow-up schedule according to a strict protocol. It
is, to our knowledge, the first report on the effects of L/
progesteron treatment in FtM adolescents with GD and
one of the few studies reporting on CSH treatment in
GD adolescents.
Conclusions
This study shows that treatment of FtM adolescents with
L effectively and significantly decreases the overall estro-
genic to androgenic ratio within 6 months and that it
can be used as a safe and cheap alternative to GnRHa to
suppress menses. However, although no direct compari-
son has been made, it is probably less effective than
GnRHa in inducing total amenorrhea and in suppressing
gonadotropins and hence development of secondary sex
characteristics. Therefore, L is specifically indicated in
adolescents with advanced pubertal development and in
situations where GnRHa are not reimbursed, to reduce
psychological burden while they are awaiting eligibility
for cross-sex hormone treatment.
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